Close Menu

NEW YORK – With $16 million in recently closed Series B funding, Israeli digital microscopy firm Scopio Labs is expanding its commercial operations including a planned US Food and Drug Administration submission for automated hematology diagnostics.

Last month, Scopio received the CE mark for its automated peripheral blood smear system, called X100 Full-Field PBS. The company is currently finishing a multicenter study of the system at sites inside and outside the US that it plans to use as part of an FDA 510(k) submission.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.